Skip to main content
. 2024 Feb 7;29(3):270–e413. doi: 10.1093/oncolo/oyad331

Table 3.

Responses to pembrolizumab and Y90 combination treatment by RECIST 1.1.

RECIST 1.1 category Current RECIST response Best RECIST response
N Percent (95% CI) Counts Percent (95% CI)
ORR 5 19.2 (6.6%, 39.4%) 8 30.8 (14.3%, 51.8%)
CR 0 0
PR 5 19.2 (6.6%, 39.4%) 8 30.8 (14.3%, 51.8%)
SD 5 19.2 (6.6%, 39.4%) 14 53.8 (33.4%, 73.4%)
PD 16 61.5 (40.6%, 79.8%) 4 15.4 (4.4%, 34.9%)